Company Analysis Actuate Therapeutics, Inc. Common stock
1. Summary
Advantages
- Price (5.39 $) is less than fair price (10.89 $)
Disadvantages
- Dividends (0%) are below the sector average (0%).
- The stock's return over the last year (-50.88%) is lower than the sector average (-30.78%).
- The company's current efficiency (ROE=54.83%) is lower than the sector average (ROE=385.88%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Actuate Therapeutics, Inc. Common stock | Index | ||
|---|---|---|---|
| 7 days | -10.7% | 30.7% | 0.1% |
| 90 days | -31.3% | -1.2% | -0.9% |
| 1 year | -50.9% | -30.8% | 18.8% |
ACTU vs Sector: Actuate Therapeutics, Inc. Common stock has significantly underperformed the "" sector by -20.1% over the past year.
ACTU vs Market: Actuate Therapeutics, Inc. Common stock has significantly underperformed the market by -69.68% over the past year.
Stable price: ACTU is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ACTU with weekly volatility of -0.98% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (5.39 $) is lower than the fair price (10.89 $).
Price significantly below the fair price: The current price (5.39 $) is 102% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-2.49) is higher than that of the sector as a whole (-335.61).
P/E vs Market: The company's P/E (-2.49) is higher than that of the market as a whole (-101.02).
5.3. P/BV
P/BV vs Sector: The company's P/BV (639.69) is higher than that of the sector as a whole (-1320.1).
P/BV vs Market: The company's P/BV (639.69) is higher than that of the market as a whole (72.02).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (28.76).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (114).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.31) is higher than that of the sector as a whole (-870.14).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.31) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-46.03%).
6.4. ROE
ROE vs Sector: The company's ROE (54.83%) is lower than that of the sector as a whole (385.88%).
ROE vs Market: The company's ROE (54.83%) is higher than that of the market as a whole (-6.21%).
6.6. ROA
ROA vs Sector: The company's ROA (-443.16%) is lower than that of the sector as a whole (-51.45%).
ROA vs Market: The company's ROA (-443.16%) is lower than that of the market as a whole (38.61%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.79%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
